Singhal Tarun, Cicero Steven, Gale Seth A, Horan Nicolas, Dubey Shipra, Marshall Gad A, Weiner Howard L
Department of Neurology, PET Imaging Program in Neurologic Diseases, Ann Romney Center for Neurologic Diseases.
Department of Neurology, Brigham Multiple Sclerosis Center.
Clin Nucl Med. 2025 Aug 1;50(8):756-757. doi: 10.1097/RLU.0000000000005955. Epub 2025 May 13.
A 78-year-old man with moderate Alzheimer disease (AD) dementia was treated with nasal-foralumab, a fully human anti-CD3 monoclonal antibody, as part of a Food and Drug Administration expanded-access-program, based on previously demonstrated efficacy of anti-CD3 antibody in animal models. 18 F-PBR06-PET, utilizing a second-generation 18-kDa-translocator-protein ligand targeting microglia, showed diffuse reduction of radiotracer uptake throughout the brain, following 3 months of nasal-foralumab compared with baseline. In particular, precuneus, posterior cingulate and anterior cingulate gyri, regions that had high levels of amyloid deposition on a baseline 18 F-Florbetapir-PET scan, showed reduction in microglial activation after nasal-foralumab treatment for 3 months.
一名患有中度阿尔茨海默病（AD）痴呆症的78岁男性，作为美国食品药品监督管理局扩大准入计划的一部分，接受了全人源抗CD3单克隆抗体鼻内注射福拉鲁单抗的治疗，这是基于先前在动物模型中证明的抗CD3抗体的疗效。利用第二代靶向小胶质细胞的18 kDa转运体蛋白配体的18F-PBR06-PET显示，与基线相比，鼻内注射福拉鲁单抗3个月后，全脑放射性示踪剂摄取弥漫性减少。特别是，在基线18F-氟代贝他吡PET扫描中淀粉样蛋白沉积水平较高的楔前叶、后扣带回和前扣带回，在鼻内注射福拉鲁单抗治疗3个月后，小胶质细胞活化减少。
